All Articles

Gilgamesh Psychedelic Trial Shows Promise in Mental Health and Beyond

December 11, 2023
x min read

Yet another psychedelic medicine clinical trial is showing promise for transforming mental health treatments.

What’s happening:

  • New York based neuroscience biotechnology company Gilgamesh Pharmaceuticals has announced positive results from their Phase 1 trial of GM-2505, a novel 5-HT2A receptor agonist
  • The clinical trial concluded that single intravenous doses of GM-2505 demonstrated rapid acting psychedelic effects and were well tolerated without any meaningful adverse side effects

Why it matters:

  • While psilocybin is a naturally occurring 5-HT2A agonist, its psychedelic effects are much longer in duration
  • GM-2505 is aiming to have a much shorter duration of action to better align with how treatments would occur in a clinical setting for patients while still having a profound therapeutic effect

Going deeper:

  • Giglamesh’s novel molecule GM-2505 was originally developed for Major Depressive Disorder and Treatment Resistant Depression but after their Phase I trial they believe it may also have therapeutic potential for alcohol use disorder, anxiety disorder and obsessive compulsive disorder
  • Gilgamesh will now look to advance GM-2505 into a Phase II clinical trial

By the numbers:

  • Psychedelic effects from GM-2505 lasted between 60-90 minutes
  • Gilgamesh has raised $66M USD in venture funding since inception

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.